Entera Bio Ltd - Warrants (02/07/2023) Return on Equity

The latest ROE for ENTXW is 219.52%. That is above the Healthcare sector average of 22.76%. Investors often review this figure alongside Entera Bio Ltd - Warrants (02/07/2023)'s historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, ENTXW currently prints 219.52% for ROE, while the sector average sits near 22.76%. That is roughly 864.3% above the sector mean. Large gaps often invite a closer look at Entera Bio Ltd - Warrants (02/07/2023)'s growth, margins, and balance sheet.

Return on Equity shows how effectively Entera Bio Ltd - Warrants (02/07/2023) converts resources into returns. At 219.52%, ENTXW may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting ENTXW's ROE (219.52%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Entera Bio Ltd - Warrants (02/07/2023)'s ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.